Skip to main content

Featured Article: Immunotherapy for glioblastoma: the promise of combination strategies


New Content Item

Glioblastoma (GBM) treatment has remained almost unchanged for more than 20 years. The current standard of care involves surgical resection (if possible) followed by concomitant radiotherapy and chemotherapy. In recent years, immunotherapy strategies have revolutionized the treatment of many cancers, increasing the hope for GBM therapy. However, mostly due to the high, multifactorial immunosuppression occurring in the microenvironment, the poor knowledge of the neuroimmune system and the presence of the blood−brain barrier, the efficacy of immunotherapy in GBM is still low. Recently, new strategies for GBM treatments have employed immunotherapy combinations and have provided encouraging results in both preclinical and clinical studies. The lessons learned from clinical trials highlight the importance of tackling different arms of immunity. 

In this review, we aim to summarize the preclinical evidence regarding combination immunotherapy in terms of immune and survival benefits for GBM management. The outcomes of recent studies assessing the combination of different classes of immunotherapeutic agents will be discussed. 

Finally, future strategies to ameliorate the efficacy of immunotherapy and facilitate clinical translation will be provided to address the unmet medical needs of GBM.

Aims and scope

Journal of Experimental & Clinical Cancer Research is an online peer-reviewed journal that provides a high-quality forum for all aspects of basic, clinical and translational work in oncology.

Please click here to read more.

Editor-in-Chief

Mauro Castelli, Regina Elena National Cancer Institute, Italy

If you would like to contact Journal of Experimental & Clinical Cancer Research, please send an email to: 

editorialjeccr@gmail.com

Articles

Springer Nature Oncology Portfolio

Discover the range of academic oncology titles at Springer Nature here.

Colorectal Cancer Awareness Month

In recognition of Colorectal Cancer Awareness Month this March, we have selected a collection of articles on colorectal cancer from across our open access portfolio. Together, these articles contribute to the evolving landscape of colorectal cancer research and the fight against this prevalent and impactful disease.
© Mopic / stock.adobe.com

Call for papers: Charting the Tumor Immune Microenvironment: Advances in Spatial Profiling and Novel Therapeutic Avenues

New Content Item

Journal of Experimental & Clinical Cancer Research is delighted to announce a new thematic series focused on: 

Charting the Tumor Immune Microenvironment: Advances in Spatial Profiling and Novel Therapeutic Avenues 

The Special Issue will accept Research Articles and Reviews in this topic. Submit here

  • Submission opens: 1st July 2024 
  • Submission deadline: 30th June 2025 

Click here to view this collection. Click here to access all thematic series published to date in Journal of Experimental & Clinical Cancer Research. 

Call for papers: Liquid Biopsy in Precision Oncology

New Content Item

Journal of Experimental & Clinical Cancer Research is delighted to announce a new thematic series focused on:

Liquid Biopsy in Precision Oncology

The Special Issue will accept Research Articles and Reviews in this topic. Submit here.

  • Submission opens: 1st February 2024
  • Submission deadline: 31st January 2025

Click here to view this collection. Click here to access all thematic series published to date in Journal of Experimental & Clinical Cancer Research.

Follow JECCR on Social Media

Social Media IconsTwitter

Facebook

LinkedIn

Follow JECCR's social media accounts to be kept up-to-date with the latest articles, collections and journal news!

Recognising Editorial Excellence

SN Editorial Excellence badgeJournal of Experimental & Clinical Cancer Research is a top rated Springer Nature journal. Prof. Mauro Castelli and the editorial team performed in the top percentile of journals based on data collected from the Journal Author Satisfaction Survey. We are recognising extraordinary editors for their commitment and passion to their journals. Read more about editorial excellence here.

Reviewer Acknowledgement and New Recruitment

The Editor-in-Chief of Journal of Experimental & Clinical Cancer Research would like to thank all of our reviewers who have contributed to the journal and is looking for new reviewers to assess manuscripts. For consideration, please send your CV with keywords and expertise to editorialjeccr@gmail.com

Archival content

Journal of Experimental & Clinical Cancer Research has been publishing since 1982.  Prior to publishing with BioMed Central from 2008, Journal of Experimental & Clinical Cancer Research was published in print.  For enquiries about previous content, please contact us on: 

editorialjeccr@gmail.com


Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 11.4
    5-year Journal Impact Factor: 11.4
    Source Normalized Impact per Paper (SNIP): 1.770
    SCImago Journal Rank (SJR): 2.806

    Speed 2023
    Submission to first editorial decision (median days): 5
    Submission to acceptance (median days): 100

    Usage 2023
    Downloads: 3,003,080
    Altmetric mentions: 3,022